ASP Isotopes has entered an agreement to supply Isotopia with enriched gadolinium-160 (Ga-160) for producing terbium-161 (Tb-161), a medical isotope used in targeted cancer radiotherapeutics.
The four-year supply agreement will commence in 2026 and is valued at $1 million per year. The Ga-160 supply will allow Isotopia to scale production and advance its Tb-161 drug candidates toward commercialization, with production taking place at the company’s facilities in Indianapolis, IN, according to the vendors.
Isotopia is collaborating with researchers to develop Tb-161-based therapies for prostate cancer, neuroendocrine tumors, and other malignancies, the companies noted in a release.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
